Vicore Pharma (VICO) investor relations material

Strategic vision and financial position

• Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology, focusing on rare lung diseases.

• Publicly listed with a $341M market cap and $111M in financial reserves as of Q1 2026, providing funding well past Phase 2b data.

• Operations span Stockholm, Cambridge (MA), and Copenhagen, with backing from leading US and European specialist investors.

Pipeline and clinical development

• Lead asset buloxibutid is a first-in-class oral AT2 receptor agonist, in a global Phase 2b trial (ASPIRE) for idiopathic pulmonary fibrosis (IPF), with Orphan Drug and Fast Track designations.

• Enrollment for the 52-week Phase 2b ASPIRE trial is complete, targeting topline data in mid-2027.

• Additional ATRAGS compounds are in preclinical development for multiple indications.

Market opportunity and unmet need

• IPF affects ~150,000 in the US and ~3 million globally, with high unmet need due to limited efficacy and tolerability of current therapies.

• The global IPF market is projected to grow from $4.2B in 2024 to over $10B by 2030-2033, driven by new approvals, increased diagnosis, and demand for disease-modifying therapies.